» Articles » PMID: 33846533

Inhibition of MiR-99a-5p Prevents Allergen-driven Airway Exacerbations Without Compromising Type-2 Memory Responses in the Intestine Following Helminth Infection

Abstract

Acute exacerbations (AE) of asthma, remain one of the biggest concerns for patients living with asthma. As such, identifying the causes, the molecular mechanisms involved and new therapeutic interventions to prevent AE is a high priority. Immunity to intestinal helminths involves the reactivation of type-2 immune responses leading to smooth muscle contraction and mucus hypersecretion-physiological processes very similar to acute exacerbations in the airways following allergen exposure. In this study, we employed a murine model of intestinal helminth infection, using Heligmosomoides polygyrus, to identify miRNAs during active expulsion, as a system for the identification of miRNAs that may contribute to AE in the airways. Concomitant with type-2 immunity and expulsion of H. polygyrus, we identified miR-99a-5p, miR-148a-3p and miR-155-5p that were differentially regulated. Systemic inhibition of these miRNAs, alone or in combination, had minimal impact on expulsion of H. polygyrus, but inhibition of miR-99a-5p or miR-155-5p significantly reduced house dust mite (HDM)-driven acute inflammation, modelling human acute exacerbations. Immunological, pathological and transcriptional analysis identified that miR-155-5p or miR-99a-5p contribute significantly to HDM-driven AE and that transient inhibition of these miRNAs may provide relief from allergen-driven AE, without compromising anti-helminth immunity in the gut.

Citing Articles

Exploring microRNA-Mediated Immune Responses to Soil-Transmitted Helminth and Herpes Simplex Virus Type 2 Co-Infections.

Pillay R, Naidoo P, Mkhize-Kwitshana Z Diseases. 2025; 13(1).

PMID: 39851470 PMC: 11765296. DOI: 10.3390/diseases13010006.


miR-99a-5p: A Potential New Therapy for Atherosclerosis by Targeting mTOR and Then Inhibiting NLRP3 Inflammasome Activation and Promoting Macrophage Autophagy.

Wang G, Jing S, Liu G, Guo X, Zhao W, Jia X Dis Markers. 2022; 2022:7172583.

PMID: 35968506 PMC: 9374553. DOI: 10.1155/2022/7172583.


Exploration of the Molecular Mechanisms of Boriss Treatment of Asthma in an mRNA-miRNA Network via Bioinformatics Analysis.

Cai Z, Liu M, Yuan F, Zeng L, Zhao K, Sun T Biomed Res Int. 2022; 2022:7111901.

PMID: 35572723 PMC: 9098316. DOI: 10.1155/2022/7111901.


circ_0075943 Dominates the miR-141-3p/AK2 Network to Support the Development of Breast Carcinoma.

Wang H, Zhao X, Wang H J Oncol. 2021; 2021:4098270.

PMID: 34887922 PMC: 8651399. DOI: 10.1155/2021/4098270.

References
1.
Corren J, Parnes J, Wang L, Mo M, Roseti S, Griffiths J . Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017; 377(10):936-946. DOI: 10.1056/NEJMoa1704064. View

2.
Haldar P, Brightling C, Hargadon B, Gupta S, Monteiro W, Sousa A . Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360(10):973-84. PMC: 3992367. DOI: 10.1056/NEJMoa0808991. View

3.
Rabe K, Nair P, Brusselle G, Maspero J, Castro M, Sher L . Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018; 378(26):2475-2485. DOI: 10.1056/NEJMoa1804093. View

4.
Schulman E . Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001; 164(8 Pt 2):S6-11. DOI: 10.1164/ajrccm.164.supplement_1.2103025. View

5.
Singh A, Busse W . Asthma exacerbations. 2: aetiology. Thorax. 2006; 61(9):809-16. PMC: 2117103. DOI: 10.1136/thx.2005.045179. View